Logic-gated Switch-DARPin design enables potent, selective cytotoxicity against cells co-expressing tumor-associated antigens (TAAs) previously considered undruggable for T cell engagers Favorable safety profile, with new data indicating healthy tissues expressing either TAA remain intact

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will hold

Dosing ongoing in fully recruited dose level 2 of MP0712 Phase 1/2a study; initial safety data to be presented at North America Conference on Lung Cancer in December 2026, efficacy data expected in 2027 Emerging clinical data from lead Radio-DARPin candidate MP0712 enables strategic focus on

Attractive biodistribution supports selection of MP0730 as Radio-DARPin therapy candidate  CD70 is a clinically validated target expressed in kidney cancer and other indications First-in-human program expected to start in H2 2027 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct.

DLL3-targeting Radio-DARPin MP0712 progressing in Phase 1/2a trial, now recruiting at dose level 2; initial data expected in 2026, efficacy data expected in 2027 CD70 selected as new radio target for the treatment of kidney cancer and other indications, with clinical program start anticipated in

Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting and patient treatment ongoing Data update expected in 2027, with trial completion in 2028 Trial-in-progress poster to be presented at ESMO 2026 in October ZURICH-SCHLIEREN, Switzerland and CONCORD,

Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving precision and therapeutic efficacy Presentation outlines Radio-DARPins’ ability to match target and disease biology for improved outcomes ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026

Phase 1/2a trial of MP0712,  212 Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosing ongoing in first patients; initial data anticipated within the coming months, comprehensive efficacy data expected in 2027 Additional compassionate care work now initiated by the Nuclear

Five sites recruiting in US study of DLL3-targeting  212 Pb-labelled Radio-DARPin MP0712 Dosing ongoing in first patients, consecutively moving to subsequent dosing cycles Initial data anticipated within the coming months, comprehensive efficacy data expected in 2027 ZURICH-SCHLIEREN, Switzerland

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics